|
|
| IFN ALPHA recombinant protein |
 |
|
|
 |
| Catalog Number: 10-783-79387 |
|
|
|
| Related Product Names:
|
-
IFNA2 protein; IFNA2; IFN ALPHA
- RECOMBINANT CHICKEN INTERFERON ALPHA; Interferon alpha-2 |
|
- Gene Information -
Information in yellow represents specific gene information and does not necessarily represent specific product details. For more information please contact sales@genwaybio.com.
|
|
| Gene Name: IFNA2 |
Gene Name Synonym: N/A |
Gi #:
N/A |
NCBI Acc #:
NP_000596.2 |
Swiss Prot Acc #:
P42165 |
Length (aa): N/A |
Mol. Weight (Da): 21550 |
Chrom Location: N/A |
|
|
 Specificity: IFN ALPHA
NCBI Gene ID: 396398
Activity: 1x107units/mg
Specificity Note: Chicken Interferon alpha (IFN alpha) shares structural and biological properties with mammalian IFN1. Recombinant chicken IFN alpha (rChIFNa) has been shown to act as a highly potent anti-viral agent in vitro (1), and also resulted in a noticeable delay in the progression of tumours in CC progressor chickens infected with Rous Sarcoma Virus, when admimistered intravenously (2).
MW: 19kD
Preparation: Recombinant protein prepared from E.coli
Buffer Solution: Phosphate buffered saline. 1M Sodium Chloride. 0.05M Sodium Acetate. 2M Urea. 10mM Beta-Mercaptoethanol
Preservative Stabilisers: None present
Product Form: Purified recombinant protein expressed in E.Coli - liquid.
Purity/Purification: >85% by Ni chelate chromatography
Crossreactivity: Chicken
Format: Rec. Protein
Storage: Store at -20 degree C only.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein.
This product should be stored undiluted.
Should this product contain a precipitate we recommend microcentrifugation before use.
Stability: 3 months from date of despatch.
Shipping: Products may be shipped on ice pack or dry ice. |
|
| APPLICATIONS for IFNA2 PROTEIN: |
| FA: Tested |
|
|
|
|
| IFNA2 PROTEIN TARGET DESCRIPTION: |
Synonym Names for IFNA2 protein: IFNA2; RECOMBINANT CHICKEN INTERFERON ALPHA; Interferon alpha-2
Function: Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase.
Subcellular Location: Secreted.
Polymorphism: Three forms exist; alpha-2a (shown here), alpha-2b and alpha-2c.
Pharmaceutical: Available under the names Roferon-A (Roche) or Intron-A (Schering-Plough). Used as an anticancer drug for its antiproliferative activity.
Similarity: Belongs to the alpha/beta interferon family.
IFN ALPHA reacts with chicken.
OMIM: 147562; gene. [NCBI / EBI]
Pathways:
KEGG pathway: Antigen processing and presentation 04612
KEGG pathway: Cytokine-cytokine receptor interaction 04060
KEGG pathway: Jak-STAT signaling pathway 04630
KEGG pathway: Natural killer cell mediated cytotoxicity 04650
KEGG pathway: Regulation of autophagy 04140
KEGG pathway: Toll-like receptor signaling pathway 04620
|
|
|
SUGGESTED PROTEIN REAGENTS - GenWay offers reagents to facilitate your research with cell-based assays, Mass Spectrometry, standards, calibrators, Western blot, cell culture, antibiotics, microwell substrates, and more!
|
|
| BACKGROUND
REFERENCES for IFNA2 PROTEIN: |
| Background references for antibody target are not specific to GenWay products |
| 1. Schultz. U. et al. (1995) Recombinant chicken interferon: a potent antiviral agent that lacks intrinsic macrophage activating factor activity. 2. Plachy. J. et al. (1999) Protective effects of Type I and Type II interferons toward Rous Sarcoma Virus-induced tumors in chickens. 3. Schwarz. H. et al. (2004) Synthesis of IFN-beta by virus-infected chicken embryo cells demonstrated with specific antisera and a new bioassay. 4. Schultz. U. et al. (1995) Recombinant chicken interferon from Escherichia coli and transfected COS cells is biologically active. |
|
Order Confirmation: Sales order confirmations are sent out upon the receipt of all orders. Please contact GenWay if you do not receive a confirmation within 1 business day of submitting your order.
Precautions: IFNA2 protein is for in vitro research use only. Not for use in diagnostics or therapeutic procedures.
Important Notes: During shipment, small volumes of IFNA2 protein vial. For products with volumes of 200 µL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Actual concentration, volume and quantity will be printed on the vial's label. Please refer to the vials label for this information.
Copyright: This GenWay TDS is copyrighted. This datasheet is produced based partially on data from Swiss-Prot/TrEMBL and NCBI. To better serve our clients with everything we know about IFNA2 protein, all related information, articles, resources about IFNA2 protein are being stored on our online database. Let us know if you have questions regarding this product.
Disclaimer: For documents and software available from this server, GenWay neither warrants nor assumes any legal liability or responsibility for the accuracy, completeness or utility of any information, product or process disclosed. |
|
|
|
GenWay is a Protein and Antibody Solutions Provider. Customer Satisfaction is Our Top Priority.
|
GenWay has a diverse line of recombinant protein expression platforms, including E. coli expression, Bacliovirus expression, yeast expression, and mammalian expression. Combining the technologies of bioinformatics, protein domain analysis, gene codon optimization, protein fusion, and protein expression in different host cells, GenWay can produce soluble and functional proteins. In particular, GenWay has the capability and vector systems for expression of difficult proteins such as proteases, kinases, glycosylated and membrane proteins. We have a very high success rate (almost 100%) and can deliver the proteins in a timely fashion. This is a core competency necessary for efficient and effective production of immunogens and affinity ligands for antibody production and purification. GenWay has over 300 recombinant proteins offered in our catalog. |
|
|
